Phase Ib study of AVB-S6-500 (axl inhibition) in combination with durvalumab (MEDI4736) in patients with platinum-resistant, recurrent epithelial ovarian cancer (NCT04019288) (320)

Emily Hinchcliff,Kathryn Lito,Anil Sood,Karen Lu,Bryan Fellman,Elisabeth Gardiner,Ying Yuan,Amir Jazaeri,Kelly Rangel,Virginia Bayer,Shannon Westin

doi:10.1016/s0090-8258(22)01542-6

Phase Ib study of AVB-S6-500 (axl inhibition) in combination with durvalumab (MEDI4736) in patients with platinum-resistant, recurrent epithelial ovarian cancer (NCT04019288) (320)

Emily Hinchcliff, Kathryn Lito + Show 9 more

https://doi.org/10.1016/s0090-8258(22)01542-6

Copy DOI

Export

Save

Cite

Journal: Gynecologic Oncology

Publication Date: Aug 1, 2022

Affiliation: Northwestern University, The University of Texas MD Anderson Cancer Center, NatureServe

#Platinum-resistant Ovarian Cancer #Bayesian Optimal Interval #AXL Inhibition #Modified RECIST V1 #High-grade Serous Histology #Immune Targeting Agents #Bayesian Optimal Interval Design #Durvalumab Therapy #Non-medical Causes #Immune Checkpoint Blockade

Abstract
Full-Text
Similar Papers

Abstract

Listen

Phase Ib study of AVB-S6-500 (axl inhibition) in combination with durvalumab (MEDI4736) in patients with platinum-resistant, recurrent epithelial ovarian cancer (NCT04019288) (320)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Gynecologic Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Phase Ib study of AVB-S6-500 (axl inhibition) in combination with durvalumab (MEDI4736) in patients with platinum-resistant, recurrent epithelial ovarian cancer (NCT04019288) (320)